U S Physical Therapy (USPH) reported $781M in revenue for fiscal 2025, +16.3% year on year. That ranks #1933 by revenue among 2853 SEC filers and #181 in Healthcare. Net income was $39.6M, a net margin of 5.1%. Revenue has grown 9.1% a year on average since 2016 ($357M then). The fiscal 2025 balance sheet shows $1.2B in total assets, $35.6M in cash and $153M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $781M | +16.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $150M | +20.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $86.7M | +37.6% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $39.6M | +26.0% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $75.1M | +0.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $14.1M | +53.2% | FY20252025-12-31 |
| Total assetsAssets | $1.2B | +3.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $476M | −2.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $35.6M | −14.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $153M | +7.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $198M | $5.0M | Open → |
| Q2 20262026-06-30 | $214M | $9.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- U S Physical Therapy Inc
- Ticker
- USPH
- Exchange
- NYSE
- SIC classification
- Services-Health Services (8000)
- Fiscal year end
- 12-31
- CIK
- 0000885978
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ascendis PharmaASND | $814M | −$258M |
| Caris Life SciencesCAI | $812M | −$68.1M |
| Telix PharmaceuticalsTLX | $804M | −$7.1M |
| U S Physical TherapyUSPH | $781M | $39.6M |
| Collegium PharmaceuticalCOLL | $781M | $63.0M |
| Alphatec HoldingsATEC | $764M | −$143M |
| Corcept TherapeuticsCORT | $761M | $99.7M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=U S Physical Therapy — Key figures |url=https://companiesranked.com/en/company/u-s-physical-therapy |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). U S Physical Therapy — Key figures. CompaniesRanked. https://companiesranked.com/en/company/u-s-physical-therapyBibTeX
@misc{companiesranked-en-company-u-s-physical-therapy-2026,
author = {{CompaniesRanked}},
title = {{U S Physical Therapy — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/u-s-physical-therapy}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001140361-26-007170 · February 27, 2026
{{cite web |title=U S Physical Therapy — Key figures — 10-K (0001140361-26-007170) |url=https://www.sec.gov/Archives/edgar/data/885978/000114036126007170/ef20060831_10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.